Organization · Other
Oncode Accelerator
Oncode Accelerator is a public-private partnership based in Utrecht, Netherlands, focused on advancing preclinical cancer drug development through innovative technologies and patient data integration. It supports oncology research by funding Demonstrator Projects that aim to translate scientific discoveries into effective therapies.
Overview
What Oncode Accelerator does
What Oncode Accelerator is
Oncode Accelerator is a public-private partnership based in Utrecht, Netherlands, focused on advancing preclinical cancer drug development through innovative technologies and patient data integration. It supports oncology research by funding Demonstrator Projects that aim to translate scientific discoveries into effective therapies.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Other
- Founded
- Founded in 2021
- Approximate age
- About 5 years
- Structured capabilities
- Funder
- Last reviewed
- May 5, 2026
Official channels
Find Oncode Accelerator elsewhere
Open the official website or a supported primary organization account.
Capability profile
Oncode Accelerator as a funder
Investment thesis
Oncode Accelerator aims to optimize and accelerate new cancer therapy development by integrating patient biology into the preclinical development process early, utilizing patient cohorts, organoids, and artificial intelligence across various therapeutic workstreams.
Focus narrative
Oncode Accelerator invests in the preclinical development of cancer therapies, specifically targeting small molecules, biologics, cell & gene therapy, and therapeutic vaccines. The organization employs innovation platforms such as Patient Cohorts, Organoids, and Artificial Intelligence to enhance the development of personalized and effective therapies.
Value beyond capital
Oncode Accelerator provides significant value to portfolio companies by offering funding, project management, scientific infrastructure, and access to patient cohorts, organoid models, and AI-enabled development tools. This support helps de-risk oncology assets and accelerates their path to clinical candidates.
Terms and economics
- Typical check
- $0–$1,500,000
- Sweet spot
- $0
Focus and fit
- Stages
- Pre-seed · Seed · Seed+
- Regions
- Global · Europe
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 5
Portfolio context
Oncode Accelerator supports various Demonstrator Projects, including: Loma Therapeutics (Denmark): Developing an immunotherapy for HPV-related cancers. Cumulus Oncology (Scotland): Working on a novel small molecule therapy for colorectal cancer. JJP Biologics: Collaborating with UMC Utrecht on a GD2-targeting bispecific antibody for neuroblastoma. UPyTher: A Dutch biotech startup focusing on treatment for peritoneal metastases. Omivera: An Oncode Institute spin-off around the CellEKT chemical proteomics platform.
Common questions
What to know about Oncode Accelerator
Upseed classifies Oncode Accelerator under the Other organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 5, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.